Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R L Basser

Showing results (11-20 of 38) with videos related to

Pageof 4
Sort By:
Drug Safety|December 1, 1996
A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapyR Abraham, R L Basser, M D Green
Diagnostic Cytopathology|April 2, 1998
Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte-colony-stimulating factor after high-dose chemotherapyI A Busmanis, A E Beaty, R L Basser
The Australian and New Zealand Journal of Surgery|November 1, 1994
Conservative management of squamous cell carcinoma of the anal canalR L Basser, J G Smith, V Worotniuk, et al.
Blood|September 15, 1995
Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone?A W Roberts, C G Begley, A P Grigg, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancerR L Basser, M D Green, W P Sheridan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 1999
Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancerR L Basser, R Abraham, L B To, et al.
Australian and New Zealand Journal of Medicine|December 1, 1991
Recombinant alpha-2b interferon in patients with malignant carcinoid tumourR L Basser, G J Lieschke, W P Sheridan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancyR L Basser, M M Sobol, G Duggan, et al.
British Journal of Haematology|April 7, 1999
Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factorM M Roberts, B W Swart, P J Simmons, et al.
British Journal of Haematology|August 6, 2000
Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assayM J Horsfall, C H Hui, L B To, et al.
Pageof 4

Showing results (11-20 of 38) with videos related to

Sort By:
Pageof 4
Drug Safety|December 1, 1996
A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapyR Abraham, R L Basser, M D Green
Diagnostic Cytopathology|April 2, 1998
Isolated pleural effusion with hematopoietic cells of mixed lineage in a patient receiving granulocyte-colony-stimulating factor after high-dose chemotherapyI A Busmanis, A E Beaty, R L Basser
The Australian and New Zealand Journal of Surgery|November 1, 1994
Conservative management of squamous cell carcinoma of the anal canalR L Basser, J G Smith, V Worotniuk, et al.
Blood|September 15, 1995
Do steady-state peripheral blood progenitor cell (PBPC) counts predict the yield of PBPC mobilized by filgrastim alone?A W Roberts, C G Begley, A P Grigg, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Pilot study of escalating doses of carboplatin and cyclophosphamide in patients with advanced cancerR L Basser, M D Green, W P Sheridan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 17, 1999
Cardiac effects of high-dose epirubicin and cyclophosphamide in women with poor prognosis breast cancerR L Basser, R Abraham, L B To, et al.
Australian and New Zealand Journal of Medicine|December 1, 1991
Recombinant alpha-2b interferon in patients with malignant carcinoid tumourR L Basser, G J Lieschke, W P Sheridan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancyR L Basser, M M Sobol, G Duggan, et al.
British Journal of Haematology|April 7, 1999
Prolonged release and c-kit expression of haemopoietic precursor cells mobilized by stem cell factor and granulocyte colony stimulating factorM M Roberts, B W Swart, P J Simmons, et al.
British Journal of Haematology|August 6, 2000
Combination of stem cell factor and granulocyte colony-stimulating factor mobilizes the highest number of primitive haemopoietic progenitors as shown by pre-colony-forming unit (pre-CFU) assayM J Horsfall, C H Hui, L B To, et al.
Pageof 4